Old Web
English
Sign In
Acemap
>
authorDetail
>
Lilian Siu
Lilian Siu
Princess Margaret Cancer Centre
Oncology
Internal medicine
Cancer
Medicine
Cancer cell
5
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
2021
Journal for ImmunoTherapy of Cancer
Omid Hamid
Dawn Baxter
Rachael Easton
Lilian Siu
Show All
Source
Cite
Save
Citations (0)
494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas
2021
Journal for ImmunoTherapy of Cancer
Melissa Lynne Johnson
Lilian Siu
David S. Hong
Patrick Schöffski
Vladimir Galvao
Fatima Rangwala
Robert Hernandez
Louis Gonzalez
Bo Ma
Lini Pandite
Irene Brana
Show All
Source
Cite
Save
Citations (0)
411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients
2020
Journal for ImmunoTherapy of Cancer
Anthony B. El-Khoueiry
Jacob Stephen Thomas
Anthony J. Olszanski
Nilofer S. Azad
Lewis H. Bender
Ian B. Walters
Giles F. Whalen
Diana L. Hanna
Matthew Ingham
Lilian Siu
Show All
Source
Cite
Save
Citations (0)
P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients
2020
Journal for ImmunoTherapy of Cancer
Timothy A. Yap
Daniel Vilarim Araujo
Debra L. Wood
Jean-François Denis
Tina Gruosso
Gilles Tremblay
Maureen D. OConnor-McCourt
Ria Ghosh
Sandra Sinclair
Paul Nadler
Lilian Siu
Nehal J. Lakhani
Show All
Source
Cite
Save
Citations (6)
411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients
2020
Journal for ImmunoTherapy of Cancer
Anthony B. El-Khoueiry
Jacob Stephen Thomas
Anthony J. Olszanski
Nilofer S. Azad
Lewis H. Bender
Ian B. Walters
Giles F. Whalen
Diana L. Hanna
Matthew Ingham
Lilian Siu
Show All
Source
Cite
Save
Citations (0)
1